day voiding diary, and urinary flow rate and post-voiding residual urine volume before and after its administration.RESULTS: Motor symptoms significantly improved after 1 year evaluating movement disorder rating scale (p<0.01). Significant improvements were also observed in the answers provided on urinary questionnaires after 1 year treatment (IPSS: 14.4 AE 7.6 vs. 8.5 AE 6.8, OABSS: 6.9 AE 2.8 vs. 5.5 AE 3.7; p<0.05) [breakdown: Table]. Data from the KHQ revealed that the domain of impact on life had significantly improved after 1 year treatment [Table]. And in 3-day voiding diary, nighttime urinary frequency (3.0 AE 1.6 vs. 2.4 AE 0.7; p<0.05). However, no significant changes were observed in the urinary flow rate (Qmax) or post-voiding residual urine volume (RU) between before and after 1 year administration of istradefylline (Qmax (ml/s): 10.7 AE 3.9 vs. 8.0 AE 2.8, RU (ml): 51.0 AE 60.0 vs. 40.5 AE 30.8). No adverse urological effects were observed in any patient.CONCLUSIONS: Istradefylline effectively improved not only motor symptoms, but also LUTS in patients with PD in a long-term period. And the results of the present study confirmed that adenosine A2A receptor antagonists are useful as a new pharmacological treatment for OAB in patients with PD.

Neurogene Blasenfunktionsstörungen betre en nahezu alle Menschen, die eine Rückenmarksläsion erlitten haben. Diese brauchen eine auf die individuellen Bedürfnisse abgestimmte Langzeitbetreuung. Das stellt für das urologische Management der Erkrankung eine Herausforderung dar. URO-NEWS 2016; 20 (3) Zertifizierte Fortbildung © Jürgen Rabatscher Läsionen im Rückenmark bedeuten ein erhebliches Risiko für Blase und Niere. URO-NEWS 2016; 20 (3) dergelassenen Facharzt eine persönliche Betreuung wichtig, die für die Compliance des Patienten und die urologische Tumorvorsorge unerlässlich ist.